Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alizyme
• Treatments: Renzapride

Criteria

Inclusion Criteria:

• Females with constipation predominant IBS as defined by the Rome II criteria

• Colonoscopy or sigmoidoscopy in previous 5 years showed no significant disease

Exclusion Criteria:

• Patients who have diarrhoea predominant or alternating symptom IBS

• Other gastrointestinal diseases that affect bowel transit